Publications

Iron associated lipid peroxidation in Alzheimers disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice. Thorwald M, Godoy-Lugo JA, Garcia G, Silva J, Kim M, Christensen A, Mack WJ, Head E, O’Day PA, Benayoun BA, Morgan TE, Pike CJ, Higuchi-Sanabria R, Forman HJ, Finch CE. bioRxiv [Preprint]. 2024 Jun 13:2023.03.28.534324. doi: 10.1101/2023.03.28.534324. PMID: 37034750

Central autonomic network dysfunction and plasma Alzheimer’s disease biomarkers in older adults. Lohman T, Kapoor A, Engstrom AC, Shenasa F, Alitin JPM, Gaubert A, Rodgers KE, Bradford D, Mather M, Han SD, Head E, Sordo L, Thayer JF, Nation DA. Alzheimers Res Ther. 2024 Jun 8;16(1):124. doi: 10.1186/s13195-024-01486-9. PMID: 38851772

A Neuropathology Case Report of a Woman with Down Syndrome who Remained Cognitively Stable. Liou JJ, Lou J, Nakagiri J, Yong W, Hom CL, Doran EW, Totoiu M, Lott I, Mapstone M, Keator DB, Brickman AM, Wright S, Nelson B, Lai F, Xicota L, Dang LT, Li J, Santini T, Mettenburg JM, Ikonomovic MD, Kofler J, Ibrahim T, Head E; Alzheimer Biomarker Consortium – Down Syndrome. medRxiv [Preprint]. 2024 Jun 3:2024.06.01.24308050. doi: 10.1101/2024.06.01.24308050. PMID: 38883742

Cerebrovascular disease emerges with age and Alzheimer’s disease in adults with Down syndrome. Lao P, Edwards N, Flores-Aguilar L, Alshikho M, Rizvi B, Tudorascu D, Rosas HD, Yassa M, Christian BT, Mapstone M, Handen B, Zimmerman ME, Gutierrez J, Wilcock D, Head E, Brickman AM. Sci Rep. 2024 May 29;14(1):12334. doi: 10.1038/s41598-024-61962-y. PMID: 38811657

Neuropathological findings in Down syndrome, Alzheimer’s disease and control patients with and without SARS-COV-2: preliminary findings. Granholm AE, Englund E, Gilmore A, Head E, Yong WH, Perez SE, Guzman SJ, Hamlett ED, Mufson EJ. Acta Neuropathol. 2024 May 27;147(1):92. doi: 10.1007/s00401-024-02743-9. PMID: 38801558

Correlating hippocampal and amygdala volumes with neuropathological burden in neurodegenerative diseases using 7T postmortem MRI. Liou JJ, Li J, Berardinelli J, Jin H, Santini T, Noh J, Farhat N, Wu M, Aizenstein H, Mettenburg JM, Yong W, Head E, Ikonomovic M, Ibrahim T, Kofler J; Alzheimer’s Biomarker Consortium on Down syndrome study. medRxiv [Preprint]. 2024 May 15:2024.05.15.24307354. doi: 10.1101/2024.05.15.24307354. PMID: 38798514

Age-Related Brain Atrophy and the Positive Effects of Behavioral Enrichment in Middle-Aged Beagles. Noche JA, Radhakrishnan H, Ubele MF, Boaz K, Mefford JL, Jones ED, van Rooyen HY, Perpich JA, McCarty K, Meacham B, Smiley J, Bembenek Bailey SA, Puskás LG, Powell DK, Sordo L, Phelan MJ, Norris CM, Head E, Stark CEL. J Neurosci. 2024 May 15;44(20):e2366232024. doi: 10.1523/JNEUROSCI.2366-23.2024. PMID: 38561226

A pathway linking pulse pressure to dementia in adults with Down syndrome. Rizvi B, Lao PJ, Sathishkumar M, Taylor L, Queder N, McMillan L, Edwards NC, Keator DB, Doran E, Hom C, Nguyen D, Rosas HD, Lai F, Schupf N, Gutierrez J, Silverman W, Lott IT, Mapstone M, Wilcock DM, Head E, Yassa MA, Brickman AM. Brain Commun. 2024 May 9;6(3):fcae157. doi: 10.1093/braincomms/fcae157. eCollection 2024. PMID: 38764776

The interactive effect of intra-beat and inter-beat blood pressure variability on neurodegeneration in older adults. Lohman T, Shenasa F, Sible I, Kapoor A, Engstrom AC, Dutt S, Head E, Sordo L, M Alitin JP, Gaubert A, Nguyen A, Nation DA. medRxiv [Preprint]. 2024 May 3:2024.05.01.24306724. doi: 10.1101/2024.05.01.24306724. PMID: 38746307

Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer’s disease: a cross-sectional study. Wisch JK, McKay NS, Boerwinkle AH, Kennedy J, Flores S, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O’Bryant SE, Price JC, Laymon CM, Krinsky-McHale SJ, Lai F, Rosas HD, Hartley SL, Zaman S, Lott IT, Tudorascu D, Zammit M, Brickman AM, Lee JH, Bird TD, Cohen A, Chrem P, Daniels A, Chhatwal JP, Cruchaga C, Ibanez L, Jucker M, Karch CM, Day GS, Lee JH, Levin J, Llibre-Guerra J, Li Y, Lopera F, Roh JH, Ringman JM, Supnet-Bell C, van Dyck CH, Xiong C, Wang G, Morris JC, McDade E, Bateman RJ, Benzinger TLS, Gordon BA, Ances BM; Alzheimer’s Biomarker Consortium-Down syndrome; Dominantly Inherited Alzheimer Network. Lancet Neurol. 2024 May;23(5):500-510. doi: 10.1016/S1474-4422(24)00084-X. PMID: 38631766

Cognitive and functional performance and plasma biomarkers of early Alzheimer’s disease in Down syndrome. Schworer EK, Handen BL, Petersen M, O’Bryant S, Peven JC, Tudorascu DL, Lee L, Krinsky-McHale SJ, Hom CL, Clare ICH, Christian BT, Schupf N, Lee JH, Head E, Mapstone M, Lott I, Ances BM, Zaman S, Brickman AM, Lai F, Rosas HD, Hartley SL; Alzheimer Biomarker Consortium‐Down Syndrome. Alzheimers Dement (Amst). 2024 Apr 14;16(2):e12582. doi: 10.1002/dad2.12582. eCollection 2024 Apr-Jun. PMID: 38623384

Whole genome-wide sequence analysis of long-lived families (Long-Life Family Study) identifies MTUS2 gene associated with late-onset Alzheimer’s disease. Xicota L, Cosentino S, Vardarajan B, Mayeux R, Perls TT, Andersen SL, Zmuda JM, Thyagarajan B, Yashin A, Wojczynski MK, Krinsky-McHale S, Handen BL, Christian BT, Head E, Mapstone ME, Schupf N, Lee JH, Barral S; Long‐Life Family Study (LLFS); Alzheimer’s Disease Genetic Consortium (ADGC); Alzheimer’s Biomarkers Consortium‐Down Syndrome (ABC‐DS). Alzheimers Dement. 2024 Apr;20(4):2670-2679. doi: 10.1002/alz.13718. Epub 2024 Feb 21. PMID: 38380866

Antibodies Raised Against an Aβ Oligomer Mimic Recognize Pathological Features in Alzheimer’s Disease and Associated Amyloid-Disease Brain Tissue. Kreutzer AG, Parrocha CMT, Haerianardakani S, Guaglianone G, Nguyen JT, Diab MN, Yong W, Perez-Rosendahl M, Head E, Nowick JS. ACS Cent Sci. 2023 Dec 21;10(1):104-121. doi: 10.1021/acscentsci.3c00592. eCollection 2024 Jan 24. PMID: 38292607

Plasma NT1-tau and Aβ₄₂ correlate with age and cognitive function in two large Down syndrome cohorts. Stern AM, Van Pelt KL, Liu L, Anderson AK, Ostaszewski B, Mapstone M, O’Bryant S, Petersen ME, Christian BT, Handen BL, Selkoe DJ, Schmitt F, Head E; Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) investigators. Alzheimers Dement. 2023 Dec;19(12):5755-5764. doi: 10.1002/alz.13382. Epub 2023 Jul 12. PMID: 37438872

Aβ and tau prions feature in the neuropathogenesis of Down syndrome. Condello C, Maxwell AM, Castillo E, Aoyagi A, Graff C, Ingelsson M, Lannfelt L, Bird TD, Keene CD, Seeley WW, Perl DP, Head E, Prusiner SB. Proc Natl Acad Sci U S A. 2022 Nov 16;119(46):e2212954119. doi: 10.1073/pnas.2212954119. Epub 2022 Nov 7. PMID: 36343257

Impact of the COVID-19 pandemic on daily life, mood, and behavior of adults with Down syndrome. Hartley SL, Fleming V, Piro-Gambetti B, Cohen A, Ances BM, Yassa MA, Brickman AM, Handen BL, Head E, Mapstone M, Christian BT, Lott IT, Doran E, Zaman S, Krinsky-McHale S, Schmitt FA, Hom C, Schupf N; ABC-DS Group. Disabil Health J. 2022 Jul;15(3):101278. doi: 10.1016/j.dhjo.2022.101278. Epub 2022 Feb 17. PMID: 35256308

Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Tcw J, Qian L, Pipalia NH, Chao MJ, Liang SA, Shi Y, Jain BR, Bertelsen SE, Kapoor M, Marcora E, Sikora E, Andrews EJ, Martini AC, Karch CM, Head E, Holtzman DM, Zhang B, Wang M, Maxfield FR, Poon WW, Goate AM. Cell. 2022 Jun 23;185(13):2213-2233.e25. doi: 10.1016/j.cell.2022.05.017. PMID: 35750033

Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice. Kiani Shabestari S, Morabito S, Danhash EP, McQuade A, Sanchez JR, Miyoshi E, Chadarevian JP, Claes C, Coburn MA, Hasselmann J, Hidalgo J, Tran KN, Martini AC, Chang Rothermich W, Pascual J, Head E, Hume DA, Pridans C, Davtyan H, Swarup V, Blurton-Jones M. Cell Rep. 2022 Jun 14;39(11):110961. doi: 10.1016/j.celrep.2022.110961. PMID: 35705056

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease. Macciardi F, Giulia Bacalini M, Miramontes R, Boattini A, Taccioli C, Modenini G, Malhas R, Anderlucci L, Gusev Y, Gross TJ, Padilla RM, Fiandaca MS, Head E, Guffanti G, Federoff HJ, Mapstone M. Geroscience. 2022 Jun;44(3):1525-1550. doi: 10.1007/s11357-022-00580-w. Epub 2022 May 19. PMID: 35585302

Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. Sawa M, Overk C, Becker A, Derse D, Albay R, Weldy K, Salehi A, Beach TG, Doran E, Head E, Yu YE, Mobley WC. Alzheimers Dement. 2022 Jun;18(6):1203-1234. doi: 10.1002/alz.12463. Epub 2021 Nov 10. PMID: 34757693

Joint-label fusion brain atlases for dementia research in Down syndrome. Queder N, Phelan MJ, Taylor L, Tustison N, Doran E, Hom C, Nguyen D, Lai F, Pulsifer M, Price J, Kreisl WC, Rosas HD, Krinsky-McHale S, Brickman AM, Yassa MA, Schupf N, Silverman W, Lott IT, Head E, Mapstone M, Keator DB; Alzheimer’s Biomarkers Consortium. Alzheimers Dement (Amst). 2022 May 25;14(1):e12324. doi: 10.1002/dad2.12324. eCollection 2022. PMID: 35634535

Obstructive sleep apnea, cerebrovascular disease, and amyloid in older adults with Down syndrome across the Alzheimer’s continuum. Lao P, Zimmerman ME, Hartley SL, Gutierrez J, Keator D, Igwe KC, Laing KK, Cotton-Samuel D, Sathishkumar M, Moni F, Andrews H, Krinsky-McHale S, Head E, Lee JH, Lai F, Yassa MA, Diana Rosas H, Silverman W, Lott IT, Schupf N, Brickman AM. Sleep Adv. 2022 May 5;3(1):zpac013. doi: 10.1093/sleepadvances/zpac013. eCollection 2022. PMID: 35669316

Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. Baumer NT, Becker ML, Capone GT, Egan K, Fortea J, Handen BL, Head E, Hendrix JE, Litovsky RY, Strydom A, Tapia IE, Rafii MS. J Neurodev Disord. 2022 Mar 23;14(1):22. doi: 10.1186/s11689-022-09435-z. PMID: 35321660

Primitive Reflexes and Dementia in Adults With Down Syndrome. Harp J, Koehl L, Van Pelt K, Head E, Jicha G, Robertson W, Lightner D, Lott I, Schmitt F. Neurol Clin Pract. 2022 Feb;12(1):6-13. doi: 10.1212/CPJ.0000000000001135. PMID: 36157622

Selective Impairment of Long-Range Default Mode Network Functional Connectivity as a Biomarker for Preclinical Alzheimer’s Disease in People with Down Syndrome. DiProspero ND, Keator DB, Phelan M, van Erp TGM, Doran E, Powell DK, Van Pelt KL, Schmitt FA, Head E, Lott IT, Yassa MA. J Alzheimers Dis. 2022;85(1):153-165. doi: 10.3233/JAD-210572. PMID: 34776436

Identifying dementia in Down syndrome with the Severe Impairment Battery, Brief Praxis Test and Dementia Scale for People with Learning Disabilities. Wallace ER, Harp JP, Van Pelt KL, Koehl LM, Caban-Holt AM, Anderson-Mooney AJ, Jicha GA, Lightner DD, Robertson WC, Head E, Schmitt FA.J Intellect Disabil Res. 2021 Dec;65(12):1085-1096. doi: 10.1111/jir.12901. Epub 2021 Nov 16.PMID: 34786786

Alzheimer’s disease associated with Down syndrome: a genetic form of dementia.Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M.Lancet Neurol. 2021 Nov;20(11):930-942. doi: 10.1016/S1474-4422(21)00245-3.PMID: 34687637

Cognitive and Behavioral Domains That Reliably Differentiate Normal Aging and Dementia in Down Syndrome. Harp JP, Koehl LM, Pelt KLV, Hom CL, Doran E, Head E, Lott IT, Schmitt FA.Brain Sci. 2021 Aug 25;11(9):1128. doi: 10.3390/brainsci11091128.PMID: 34573150

Postmortem Neocortical ³H-PiB Binding and Levels of Unmodified and Pyroglutamate Aβ in Down Syndrome and Sporadic Alzheimer’s Disease. Pivtoraiko VN, Racic T, Abrahamson EE, Villemagne VL, Handen BL, Lott IT, Head E, Ikonomovic MD.Front Aging Neurosci. 2021 Aug 13;13:728739. doi: 10.3389/fnagi.2021.728739. eCollection 2021.PMID: 34489686

Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Carmona-Iragui M, Alcolea D, Barroeta I, Videla L, Muñoz L, Van Pelt KL, Schmitt FA, Lightner DD, Koehl LM, Jicha G, Sacco S, Mircher C, Pape SE, Hithersay R, Clare ICH, Holland AJ, Nübling G, Levin J, Zaman SH, Strydom A, Rebillat AS, Head E, Blesa R, Lleó A, Fortea J.Lancet Neurol. 2021 Aug;20(8):605-614. doi: 10.1016/S1474-4422(21)00129-0.PMID: 34302785

Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease. Morabito S, Miyoshi E, Michael N, Shahin S, Martini AC, Head E, Silva J, Leavy K, Perez-Rosendahl M, Swarup V.Nat Genet. 2021 Aug;53(8):1143-1155. doi: 10.1038/s41588-021-00894-z. Epub 2021 Jul 8.PMID: 34239132

APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for All.Lemere CA, Head E, Holtzman DM.JAMA Neurol. 2021 Aug 1;78(8):913-915. doi: 10.1001/jamaneurol.2021.1649.PMID: 34228117

Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain.Radhakrishnan H, Ubele MF, Krumholz SM, Boaz K, Mefford JL, Jones ED, Meacham B, Smiley J, Puskás LG, Powell DK, Norris CM, Stark CEL, Head E.J Neurosci. 2021 Jun 9;41(23):5124-5133. doi:10.1523/JNEUROSCI.0361-21.2021.Epub 2021 May 5.PMID: 33952632

Neuropathology of Aging in Cats and its Similarities to Human Alzheimer’s Disease. Sordo L, Martini AC, Houston EF, Head E, Gunn-Moore D. Front Aging. 2021 Jun 7;2:684607. doi: 10.3389/fragi.2021.684607. eCollection 2021. PMID: 35822024

Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer’s disease.Aschenbrenner AJ, Baksh RA, Benejam B, Beresford-Webb JA, Coppus A, Fortea J, Handen BL, Hartley S, Head E, Jaeger J, Levin J, Loosli SV, Rebillat AS, Sacco S, Schmitt FA, Thurlow KE, Zaman S, Hassenstab J, Strydom A.Alzheimers Dement (Amst). 2021 May 2;13(1):e12184. doi: 10.1002/dad2.12184. eCollection 2021.PMID: 33969175

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. Hendrix JA, Airey DC, Britton A, Burke AD, Capone GT, Chavez R, Chen J, Chicoine B, Costa ACS, Dage JL, Doran E, Esbensen A, Evans CL, Faber KM, Foroud TM, Hart S, Haugen K, Head E, Hendrix S, Hillerstrom H, Kishnani PS, Krell K, Ledesma DL, Lai F, Lott I, Ochoa-Lubinoff C, Mason J, Nicodemus-Johnson J, Proctor NK, Pulsifer MB, Revta C, Rosas HD, Rosser TC, Santoro S, Schafer K, Scheidemantel T, Schmitt F, Skotko BG, Stasko MR, Talboy A, Torres A, Wilmes K, Woodward J, Zimmer JA, Feldman HH, Mobley W.J Clin Med. 2021 Apr 28;10(9):1907. doi: 10.3390/jcm10091907.PMID: 33924960

Opportunities, barriers, and recommendations in down syndrome research. Hendrix JA, Amon A, Abbeduto L, Agiovlasitis S, Alsaied T, Anderson HA, Bain LJ, Baumer N, Bhattacharyya A, Bogunovic D, Botteron KN, Capone G, Chandan P, Chase I, Chicoine B, Cieuta-Walti C, DeRuisseau LR, Durand S, Esbensen A, Fortea J, Giménez S, Granholm AC, Hahn LJ, Head E, Hillerstrom H, Jacola LM, Janicki MP, Jasien JM, Kamer AR, Kent RD, Khor B, Lawrence JB, Lemonnier C, Lewanda AF, Mobley W, Moore PE, Nelson LP, Oreskovic NM, Osorio RS, Patterson D, Rasmussen SA, Reeves RH, Roizen N, Santoro S, Sherman SL, Talib N, Tapia IE, Walsh KM, Warren SF, White AN, Wong GW, Yi JS.Transl Sci Rare Dis. 2021;5(3-4):99-129. doi: 10.3233/trd-200090. Epub 2021 Apr 15.PMID: 34268067

Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Diana Rosas H, Zaman S, Wang MC, Tycko B, Lee JH, Handen B, Hartley S, Fortea J, O’Bryant S; Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS). J Alzheimers Dis. 2021;79(2):671-681. doi: 10.3233/JAD-201167.PMID: 33337378

Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. Lanzillotta C, Zuliani I, Tramutola A, Barone E, Blarzino C, Folgiero V, Caforio M, Valentini D, Villani A, Locatelli F, Butterfield DA, Head E, Perluigi M, Abisambra JF, Di Domenico F. Prog Neurobiol. 2021 Jan;196:101892. doi: 10.1016/j.pneurobio.2020.101892. Epub 2020 Aug 11.PMID: 32795489

A preliminary study of cerebral blood flow, aging and dementia in people with Down syndrome. Thalman S, Van Pelt KL, Lin AL, Johnson NF, Jicha G, Caban-Holt A, Robertson W, Lightner D, Powell D, Head E, Schmitt F. J Intellect Disabil Res. 2020 Dec;64(12):934-945. doi: 10.1111/jir.12784. Epub 2020 Sep 30. PMID: 32996650

Alzheimer-Related Cerebrovascular Disease in Down Syndrome. Lao PJ, Gutierrez J, Keator D, Rizvi B, Banerjee A, Igwe KC, Laing KK, Sathishkumar M, Moni F, Andrews H, Krinsky-McHale S, Head E, Lee JH, Lai F, Yassa MA, Rosas HD, Silverman W, Lott IT, Schupf N, Brickman AM. Ann Neurol. 2020 Dec;88(6):1165-1177. doi: 10.1002/ana.25905. Epub 2020 Oct 9. PMID: 32944999

Longitudinal assessment of dementia measures in Down syndrome. Koehl L, Harp J, Van Pelt KL, Head E, Schmitt FA. Alzheimers Dement (Amst). 2020 Nov 14;12(1):e12075. doi: 10.1002/dad2.12075. eCollection 2020. PMID: 33225040

The AT(N) framework for Alzheimer’s disease in adults with Down syndrome. Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Lai F, Rosas HD, Zaman S, Petersen ME, Strydom A, Fortea J, Handen B, O’Bryant S. Alzheimers Dement (Amst). 2020 Oct 27;12(1):e12062. doi: 10.1002/dad2.12062. eCollection 2020. PMID: 33134477

Distribution of microglial phenotypes as a function of age and Alzheimer’s disease neuropathology in the brains of people with Down syndrome. Martini AC, Helman AM, McCarty KL, Lott IT, Doran E, Schmitt FA, Head E. Alzheimers Dement (Amst). 2020 Oct 14;12(1):e12113. doi: 10.1002/dad2.12113. eCollection 2020. PMID: 33088896

Feasibility of dual-task gait to estimate Alzheimer’s related cognitive decline in Down syndrome. Van Pelt KL, Koehl L, Caban-Holt A, Anderson-Mooney A, Head E, Schmitt FA.Alzheimers Dement (Amst). 2020 Aug 25;12(1):e12092. doi: 10.1002/dad2.12092. eCollection 2020.PMID: 32875058

The Alzheimer’s Biomarker Consortium-Down Syndrome: Rationale and methodology. Handen BL, Lott IT, Christian BT, Schupf N, OBryant S, Mapstone M, Fagan AM, Lee JH, Tudorascu D, Wang MC, Head E, Klunk W, Ances B, Lai F, Zaman S, Krinsky-McHale S, Brickman AM, Rosas HD, Cohen A, Andrews H, Hartley S, Silverman W; Alzheimer’s Biomarker Consortium‐Down Syndrome (ABC‐DS). Alzheimers Dement (Amst). 2020 Aug 3;12(1):e12065. doi: 10.1002/dad2.12065. eCollection 2020. PMID: 32775597

Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Ellis RJ, Diaz M, Sacktor N, Marra C, Collier AC, Clifford DB, Calcutt N, Fields JA, Heaton RK, Letendre SL; CNS Antiretroviral Therapy Effects Research (CHARTER) Study Group. Ann Clin Transl Neurol. 2020 Jul;7(7):1166-1173. doi: 10.1002/acn3.51097. Epub 2020 Jul 3. PMID: 32619341

Further understanding the connection between Alzheimer’s disease and Down syndrome. Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, Kishnani PS, Lai F, Lao P, Lemere C, Mobley W, Mufson EJ, Potter H, Zaman SH, Granholm AC, Rosas HD, Strydom A, Whitten MS, Rafii MS. Alzheimers Dement. 2020 Jul;16(7):1065-1077. doi: 10.1002/alz.12112. Epub 2020 Jun 16. PMID: 32544310

Proteomic profiles for Alzheimer’s disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) study. Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott I, Rafii MS, Handen B, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas HD, Zaman S, Ances BM, Wang MC, Tycko B, Lee JH, O’Bryant S; Alzheimer’s Biomarker Consortium – Down Syndrome (ABC‐DS). Alzheimers Dement (Amst). 2020 Jun 30;12(1):e12039. doi: 10.1002/dad2.12039. eCollection 2020. PMID: 32626817

Biomarkers in Down syndrome can help us understand Alzheimer’s disease. Head E, Ances B. Lancet. 2020 Jun 27;395(10242):1951-1953. doi: 10.1016/S0140-6736(20)30916-8. PMID: 32593327

APOE genotype-dependent pharmacogenetic responses to rapamycin for prAPOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer’s disease. Lin AL, Parikh I, Yanckello LM, White RS, Hartz AMS, Taylor CE, McCulloch SD, Thalman SW, Xia M, McCarty K, Ubele M, Head E, Hyder F, Sanganahalli BG. Neurobiol Dis. 2020 Jun;139:104834. doi: 10.1016/j.nbd.2020.104834. Epub 2020 Mar 12. PMID: 32173556

Metabolic correlates of prevalent mild cognitive impairment and Alzheimer’s disease in adults with Down syndrome. Mapstone M, Gross TJ, Macciardi F, Cheema AK, Petersen M, Head E, Handen BL, Klunk WE, Christian BT, Silverman W, Lott IT, Schupf N; Alzheimer’s Biomarkers Consortium–Down Syndrome (ABC‐DS) Investigators. Alzheimers Dement (Amst). 2020 Apr 5;12(1):e12028. doi: 10.1002/dad2.12028. eCollection 2020. PMID: 32258359

Brain insulin resistance triggers early onset Alzheimer disease in Down sBrain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Tramutola A, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, Barone E. Neurobiol Dis. 2020 Apr;137:104772. doi: 10.1016/j.nbd.2020.104772. Epub 2020 Jan 24. PMID: 31987911

Brain-Blood Partition Coefficient and Cerebral Blood Flow in Canines Using Calibrated Short TR Recovery (CaSTRR) Correction Method. Thalman SW, Powell DK, Ubele M, Norris CM, Head E, Lin AL. Front Neurosci. 2019 Nov 5;13:1189. doi: 10.3389/fnins.2019.01189. eCollection 2019. PMID: 31749679

Biliverdin reductase-A impairment links brain insulin resistance with increased Aβ production in an animal model of aging: Implications for Alzheimer disease. Triani F, Tramutola A, Di Domenico F, Sharma N, Butterfield DA, Head E, Perluigi M, Barone E. Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3181-3194. doi: 10.1016/j.bbadis.2018.07.005. Epub 2018 Jul 5. PMID: 29981845

Cerebrovascular pathology in Down syndrome and Alzheimer disease. Head E, Phelan MJ, Doran E, Kim RC, Poon WW, Schmitt FA, Lott IT. Acta Neuropathol Commun. 2017 Dec 1;5(1):93. doi: 10.1186/s40478-017-0499-4. PMID: 29195510

Commentary: Building the Older Adult Fall Prevention Movement – Steps and Lessons Learned. Smith ML, Chaudhary S, Nieb S, Bayakly R, Graham K, Head E. Front Public Health. 2016 Dec 22;4:277. doi: 10.3389/fpubh.2016.00277. eCollection 2016. PMID: 28066756

Down syndrome individuals with Alzheimer’s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer’s disease. Wilcock DM, Hurban J, Helman AM, Sudduth TL, McCarty KL, Beckett TL, Ferrell JC, Murphy MP, Abner EL, Schmitt FA, Head E. Neurobiol Aging. 2015 Sep;36(9):2468-74. doi: 10.1016/j.neurobiolaging.2015.05.016. Epub 2015 May 30. PMID: 26103884

Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome? Rohn TT, McCarty KL, Love JE, Head E. J Parkinsons Dis Alzheimers Dis. 2014 Dec 8;1(1):7. doi: 10.13188/2376-922x.1000004. PMID: 25594074

A canine model of human aging and Alzheimer’s disease. Head E. Biochim Biophys Acta. 2013 Sep;1832(9):1384-9. doi: 10.1016/j.bbadis.2013.03.016. Epub 2013 Mar 23. PMID: 23528711

Alzheimer’s Disease in Down Syndrome. Head E, Powell D, Gold BT, Schmitt FA. Eur J Neurodegener Dis. 2012 Dec;1(3):353-364. PMID: 25285303

Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. Martin SB, Dowling AL, Head E. Curr Neuropharmacol. 2011 Dec;9(4):651-61. doi: 10.2174/157015911798376217. PMID: 22654723

Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, Albay R 3rd, Pensalfini A, Yeung S, Head E, Marsh JL, Glabe C. Mol Neurodegener. 2010 Dec 13;5:57. doi: 10.1186/1750-1326-5-57. PMID: 21144050

Short-term supplementation with acetyl-L-carnitine and lipoic acid alters plasma protein carbonyl levels but does not improve cognition in aged beagles. Christie LA, Opii WO, Head E, Araujo JA, de Rivera C, Milgram NW, Cotman CW. Exp Gerontol. 2009 Dec;44(12):752-9. doi: 10.1016/j.exger.2009.08.012. Epub 2009 Sep 6. PMID: 19735717

The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. Cotman CW, Head E. J Alzheimers Dis. 2008 Dec;15(4):685-707. doi: 10.3233/jad-2008-15413. PMID: 19096165

Alzheimer’s disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG. J Neurosci. 2007 Nov 14;27(46):12721-31. doi: 10.1523/JNEUROSCI.3201-07.2007. PMID: 18003852

Beta-amyloid, oxidative stress and down syndrome. Lott IT, Head E, Doran E, Busciglio J. Curr Alzheimer Res. 2006 Dec;3(5):521-8. doi: 10.2174/156720506779025305. PMID: 17168651

Nutritional management of brain aging in dogs. Roudebush P, Zicker SC, Cotman CW, Milgram NW, Muggenburg BA, Head E. J Am Vet Med Assoc. 2005 Sep 1;227(5):722-8. doi: 10.2460/javma.2005.227.722. PMID: 16178393

Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Liu J, Head E, Kuratsune H, Cotman CW, Ames BN. Ann N Y Acad Sci. 2004 Nov;1033:117-31. doi: 10.1196/annals.1320.011. PMID: 15591009

Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Haier RJ, Alkire MT, White NS, Uncapher MR, Head E, Lott IT, Cotman CW. Neurology. 2003 Dec 23;61(12):1673-9. doi: 10.1212/01.wnl.0000098935.36984.25. PMID: 14694028

Caspase Activation in the Alzheimer’s Disease Brain: Tortuous and Torturous. Rohn TT, Rissman RA, Head E, Cotman CW. Drug News Perspect. 2002 Nov;15(9):549-557. doi: 10.1358/dnp.2002.15.9.740233. PMID: 12677194

Activation of caspase-8 in the Alzheimer’s disease brain. Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH. Neurobiol Dis. 2001 Dec;8(6):1006-16. doi: 10.1006/nbdi.2001.0449. PMID: 11741396

Ultrastructural analyses of beta-amyloid in the aged dog brain: neuronal beta-amyloid is localized to the plasma membrane. Torp R, Head E, Cotman CW. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Jul;24(5):801-10. doi: 10.1016/s0278-5846(00)00107-x. PMID: 11191714

Clinical and pathological evidence for a frontal variant of Alzheimer disease. Johnson JK, Head E, Kim R, Starr A, Cotman CW. Arch Neurol. 1999 Oct;56(10):1233-9. doi: 10.1001/archneur.56.10.1233. PMID: 10520939

Magnetic resonance imaging of anatomic and vascular characteristics in a canine model of human aging. Su MY, Head E, Brooks WM, Wang Z, Muggenburg BA, Adam GE, Sutherland R, Cotman CW, Nalcioglu O. Neurobiol Aging. 1998 Sep-Oct;19(5):479-85. doi: 10.1016/s0197-4580(98)00081-5. PMID: 9880050

Effects of extended electrical kindling on exploratory behavior and spatial learning. Cammisuli S, Murphy MP, Ikeda-Douglas CJ, Balkissoon V, Holsinger RM, Head E, Michael M, Racine RJ, Milgram NW. Behav Brain Res. 1997 Dec;89(1-2):179-90. doi: 10.1016/s0166-4328(97)00059-4. PMID: 9475625

Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Cummings BJ, Satou T, Head E, Milgram NW, Cole GM, Savage MJ, Podlisny MB, Selkoe DJ, Siman R, Greenberg BD, Cotman CW. Neurobiol Aging. 1996 Jul-Aug;17(4):653-9. doi: 10.1016/0197-4580(96)00062-0. PMID: 8832640

Spatial learning and memory as a function of age in the dog. Head E, Mehta R, Hartley J, Kameka M, Cummings BJ, Cotman CW, Ruehl WW, Milgram NW. Behav Neurosci. 1995 Oct;109(5):851-8. doi: 10.1037//0735-7044.109.5.851. PMID: 8554710

Effects of L-deprenyl on manifestations of aging in the rat and dog. Ivy GO, Rick JT, Murphy MP, Head E, Reid C, Milgram NW. Ann N Y Acad Sci. 1994 Jun 30;717:45-59. doi: 10.1111/j.1749-6632.1994.tb12072.x. PMID: 8030851

The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog. Milgram NW, Ivy GO, Head E, Murphy MP, Wu PH, Ruehl WW, Yu PH, Durden DA, Davis BA, Paterson IA, et al. Neurochem Res. 1993 Dec;18(12):1211-9. doi: 10.1007/BF00975038. PMID: 8272186

Changes in spontaneous behavior in the dog following oral administration of L-deprenyl. Head E, Milgram NW. Pharmacol Biochem Behav. 1992 Nov;43(3):749-57. doi: 10.1016/0091-3057(92)90404-4. PMID: 1448469